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In the mid-20th century, there was a widespread 
belief that infectious diseases could be conquered. 
This belief has been challenged in recent decades 
by an unprecedented increase in the emergence 
or resurgence of many pathogens. The defini-
tion of an ‘emerging infectious disease’ is widely 
accepted as being a newly recognized disease or 
an existing disease that is rapidly increasing in 
incidence or extending in geographic or host 
range [1]. A collation of international efforts 
identified that approximately 75% of emerging 
pathogens are zoonotic and that emerging viruses 
are one of the disease agents most likely to be 
transmitted to humans via an animal reservoir 
[2]. Indeed, RNA viruses are held accountable 
for many outbreaks because they can be asymp-
tomatically maintained in a reservoir host spe-
cies and frequently mutate during replication due 
to the low fidelity of the virus-encoded RNA 
polymerases [3].
The dramatic rise in the emergence and 
resurgence of exotic viruses cannot be explained 
entirely by genetic recombination and mutation; 
modern environmental factors have facilitated 
their zoonotic transmission. Encroachment into 
previously remote rural areas, as a result of defor-
estation and urban expansion, brings people and 
livestock into closer proximity to viral reservoir 
hosts, increasing the risk of viral transfer between 
species. This was the case for initial henipavirus 
outbreaks throughout southeast Asia and the 
surrounding areas, where land use and intensive 
animal husbandry practices within the vicinity 
of pteropid bats exposed workers to Hendra and 
Nipah viruses via transmission through equine 
and swine intermediary amplifying hosts in Aus-
tralia in 1998 and Malaysia in 1999, respectively 
[4,5]. Increased global connectivity, air travel and 
international trade exacerbate the issue by cir-
cumventing geographical barriers to the spread 
of exotic viruses. It is commonly hypothesized 
that the introduction of West Nile virus (WNV) 
to New York in 1999 was due to air travel either 
transporting infected passengers or mosquito 
vectors from a region where the flavivirus is 
endemic. This is also a probable cause of the 
recent introduction of the novel Middle East 
respiratory syndrome coronavirus into the UK 
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Recent decades have witnessed an unprecedented rise in the outbreak 
occurrence of infectious and primarily zoonotic viruses. Contributing factors to 
this phenomenon include heightened global connectivity via air travel and 
international trade links, as well as man-made environmental alterations, such 
as deforestation and climate change, which all serve to bring humans into closer 
contact with animal reservoirs and alter the habitat of vectors, thus facilitating 
the transmission of viruses between species. Serological assays are integral to 
tracking the epidemiological spread of a virus and evaluating mass vaccination 
programs by quantifying neutralizing antibody responses raised against antigenic 
epitopes on the viral surface. However, conventional serological tests are 
somewhat marred by equipment and reagent costs, the necessity for high-
containment laboratories for studying many emerging viruses, and interlaboratory 
variability, among other issues. This review details ‘next-generation’ assays aimed 
at addressing some of the persistent problems with viral serology, focusing on 
how manipulating the genomes of RNA viruses can produce attenuated or 
chimeric viruses that can be exploited as surrogate viruses in neutralization 
assays. Despite the undoubted promise of such novel serological platforms, it 
must be remembered that these assays have to withstand rigorous validation 
and standardization measures before they can play an integral role in curtailing 
the severity of future emerging virus outbreaks.
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after its initial detection in Saudi Arabia [6,7]. 
Climate change is further altering the habitats 
of both reservoir hosts and disease-carrying vec-
tors, resulting in adapting ranges and, in turn, 
extending the potential regions for zoonotic 
transmission of exotic viruses [8]. 
Another consideration that has recently chal-
lenged conventional thought regarding the 
emergence and re-emergence of exotic viruses is 
the notion of ‘emerging diagnosis’. Human sero-
prevalence studies of Ebola and Lassa viruses, 
which cause lethal, systemic hemorrhagic fevers, 
indicate widespread exposure of the pathogens 
throughout areas of sub-Saharan Africa [9,10]. 
Furthermore, analyses of the evolutionary histo-
ries of Ebola and Lassa viruses [11,12] and putative 
evidence of the development of human genetic 
resistance against Lassa virus in Nigeria [13] sug-
gest that these viruses have been circulating for 
longer than had been realized. This has led some 
to believe that the apparent ‘boom’ in emerg-
ing pathogens may actually be a consequence of 
the development of improved and novel diag-
nostic methods unveiling the true extent of the 
circulation of viruses that have previously been 
overlooked [14]. 
Regardless of the causes, the increased emer-
gence or resurgence of exotic viruses highlights 
the vital importance of maintaining and devel-
oping high standards of diagnostic surveillance. 
Serological assays that detect antibodies, usually 
against the antigenic surface glycoproteins of 
many pathogenic viruses, are integral diagnos-
tic tools. They are readily applicable throughout 
the process of emerging viral outbreaks and offer 
distinct benefits when compared with alterna-
tive diagnostic methods. The ability to measure 
antibodies to a particular virus enables the epi-
demiological spread of an emergent disease to be 
traced even after the symptomatic stages of infec-
tion. Identification of antibodies in the absence 
of the pathogen is advantageous when viremia is 
transient and attempting to detect viral RNA or 
quantify viral load by means of reverse transcrip-
tion PCR in blood or tissue samples could result 
in a falsely negative result when testing for acute 
viral infections. Where vaccines are available, 
assessment and serosurveillance of mass vaccina-
tion programs and antiviral treatment schedules 
can also be achieved using serological assays. 
Nonetheless, conventional assays for serologi-
cal diagnosis of emerging and re-emerging exotic 
viruses present various challenges, depending on 
the particular disease outbreak. For instance, due 
to the severe pathogenicity and lack of effec-
tive vaccines or treatments for many viruses in 
families such as the Arenaviridae and Bunyaviri-
dae, handling of virus for clinical, diagnostic or 
research-based purposes is often limited to bio-
safety level 4 laboratories. This limits the capac-
ity for widespread and rapid serological diagnosis 
in many resource-poor, endemic areas. In addi-
tion, knowledge of protective immune correlates, 
such as serum neutralizing antibody levels, will 
need to be determined following the emergence 
of a novel virus such as Schmallenberg virus [15]. 
Vaccine efficacy testing can be hindered until 
protective thresholds are known. High levels of 
cross-reactivity between viruses of the same fam-
ily can also be a serious drawback for diagnosis 
using serological assays, which is a particular 
problem for members of the Flaviviridae [16,17].
This review will summarize and consider the 
advantages and drawbacks of some established 
serological assays before documenting the latest 
approaches to the detection of virus-neutralizing 
antibodies (VNAbs) and outlining where further 
advances could be made in order to improve the 
serological diagnosis of viral infections.
Traditional serological assays
There are many different approaches that may 
be taken to measure virus-specific antibodies, 
often by harnessing the properties of interac-
tion between virus and antibody, including cell 
agglutination, precipitation and complement 
fixation. This section focuses on three methods 
in common use.
The plaque reduction neutralization test 
(PRNT) is the traditional assay for the mea-
surement of VNAbs. In this assay, a series of 
dilutions of the patient sample, such as serum or 
cerebrospinal fluid, is prepared and mixed with 
a standardized amount of virus. After allowing 
time for any antibodies in the sample to bind to 
the virus, the mixture is added to a confluent 
monolayer of permissive cells. After a further 
short incubation period sufficient for virus to 
have infected the cells, the sample suspension 
is replaced with a layer of agarose or carboxy-
methylcellulose to prevent a virus that is released 
from infected cells spreading to nonadjacent 
cells. Virus infection is quantified indirectly by 
observing plaques of virus-induced cytopathic 
effect (CPE), which is measured in PFU/ml. The 
concentration of antibody in the patient sample 
that reduces the formation of plaques by a cer-
tain amount (usually 50% [PRNT
50
 ] or 90% 
[PRNT
90
]) compared with a virus control mixed 
with a sample or diluent known to be antibody 
free enables quantification of the neutralizing 
antibody present in the sample. Antibodies to 
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viruses that do not cause discernible CPE can 
be measured using a variant of the PRNT where 
the virus is detected using virus-specific antibod-
ies and, usually, fluorescence- or enzyme-labeled 
secondary antibodies. Infectivity is measured in 
FFU/ml. A less traditional approach applicable to 
viruses that neither cause CPE nor form plaques 
that are measurable in the focus-forming assay, 
and also allows primary human cells to be used, 
is flow cytometry [18,19].
A prerequisite for performing the PRNT is the 
availability of a readily cultured cell line that is 
permissive to the given virus. As mentioned ear-
lier, the necessity for using infectious virus can 
bring additional restrictions in terms of expenses 
associated with high-biosafety laboratories. The 
six- or 12-well format and as many as 6 days’ 
incubation that are required for plaque visualiza-
tion restricts assay throughput. Despite its limi-
tations, PRNT remains widely regarded as the 
gold standard for the detection of VNAbs, par-
ticularly for measuring the immune response to 
vaccination, due to its high sensitivity and speci-
ficity [20,21]. PRNT has been used in laboratories 
worldwide for many years, and as a result, varia-
tions in how the test is performed, even for the 
same virus, have arisen [22], further complicating 
international standardization.
The hemagglutination inhibition (HI) test is a 
traditional measure of antibodies to viruses that 
are able to agglutinate red blood cells, which 
includes adenoviruses, alphaviruses, bunya-
viruses, flaviviruses, influenza, parainfluenza, 
rabies and rubella. The assay is quite variable, 
particularly between laboratories, because some 
of the reagents used are difficult to standardize. 
For diagnostic purposes, this variability is less 
of an issue than the limited sensitivity because 
acute and convalescent sera will usually be tested 
in parallel in order to detect a rise in antibody 
titer. Various techniques have been applied to 
improve the sensitivity of different HI assays, 
such as bromelain treatment of goose red blood 
cells for the detection of rabies virus antibodies 
[23] or Tween® 80 (Sigma-Aldrich, MO, USA) 
and ether treatment of parainfluenza virus [24]. 
Unfortunately, these tend to increase the inher-
ent variability of the test. Another factor that 
further impairs standardization of the HI test 
is the need, in some instances, to remove non-
specific inhibitors of agglutination [25]. Different 
species vary in the inhibitors present in sera and 
failure to neutralize these using the correct pre-
treatment can lead to false-positive results. The 
HI assay continues to be widely used to assess the 
efficacy and effectiveness of influenza vaccines, 
even though it only detects antibodies that bind 
to the hemagglutinin molecule but do not neces-
sarily neutralize virus infectivity [26]. However, 
an advantage of the HI test compared with the 
PRNT is that it is quick and relatively simple 
to perform. 
ELISAs were first developed in the early 1970s 
as a safer alternative to radioimmunoassays. As 
with the HI assay, ELISA measures antibodies 
that bind to viral proteins, but these antibodies 
do not necessarily neutralize virus infectivity. 
Measuring antibodies to a specific viral protein 
can allow antibodies raised in response to infec-
tion to be differentiated from those raised to a 
vaccination – the differentiation of infected from 
vaccinated animals (DIVA) approach. This strat-
egy was used effectively during an outbreak of 
equine influenza in Australia. Horses were vacci-
nated with a canarypox-vectored vaccine express-
ing only the hemagglutinin protein of equine 
influenza. Use of a blocking ELISA that detects 
antibodies to the viral nucleoprotein enabled 
infected animals to be distinguished from vac-
cinated animals, which do not raise antibodies 
to nucleoprotein. This allowed vaccination to be 
implemented (along with movement restrictions) 
in order to rapidly bring the outbreak under 
control and enabled the Australian authorities 
to declare the region free of equine influenza [27].
On the one hand, the 96- or 384-well format 
of ELISA allows high-throughput screening, and 
the assay is also rapid. On the other hand, there 
are often limitations in specificity compared with 
PRNT. Cross-reactivity might occur with the 
secondary antibody in the indirect ELISA for-
mat. In addition, the use of purified or recombi-
nant proteins can reduce specificity due to non-
native folding and modifications to proteins. 
As well as replacing radioimmunoassays, the 
use of ELISAs has largely overtaken the use of 
the indirect immunofluorescence test (IFTs) for 
antibody detection. However, IFTs remain use-
ful; an IFT was recently proposed as a potential 
alternative to ELISA using recombinant hepatitis 
E virus proteins expressed in bacteria [28]. An 
IFT was also recently applied as a screening assay 
for the detection of antibodies to Middle East 
respiratory syndrome coronavirus [29].
Cross-reactivity of antibodies between closely 
related viruses is a particular issue for the flavi-
viruses that cause similar clinical signs and 
cocirculate in some regions. For example, den-
gue virus (DENV) often circulates in the same 
geographical regions as Japanese encephalitis 
virus (JEV), and there is increasing awareness 
that WNV is responsible for a proportion of 
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encephalitis cases in India, a country in which 
JEV also circulates [30]. It may therefore be neces-
sary to confirm a diagnosis made by ELISA using 
PRNT. Alternatively, in two widely used IgM 
antibody-capture ELISA kits, the Panbio® Japa-
nese encephalitis–Dengue IgM Combo ELISA 
(Alere, Australia) and the Venture Technologies 
Dengue–JEV modified antigen capture ELISA 
(Universiti Sains Malaysia, Malaysia), antibod-
ies to JEV and DENV are tested for in parallel 
and the higher positive value is taken to be the 
infecting virus, although no distinction is made 
between the four serotypes of DENV [31]. The 
need to test a single sample for antibodies to mul-
tiple related cocirculating pathogens increases 
the sample volume required. Cerebrospinal fluid 
is the sample of choice to verify the cause of viral 
encephalopathy, as a positive serum sample only 
demonstrates recent peripheral infection that 
may be coincidental [31]. Furthermore, JEV 
infections in India are more frequent in young 
children who have not yet developed immu-
nity as a result of exposure or vaccination [32]; 
therefore, cerebrospinal fluid sample volumes 
are usually limited. The flavi virus ELISA kits 
described measure IgM antibody as an indicator 
of recent infection; measurement of IgG requires 
demon stration of a rise in titer between acute and 
convalescent samples in order to confirm recent 
exposure to virus. However, IgM antibodies to 
flaviviruses can persist for as long as 4 months 
after infection [33,34].
‘Next-generation’ assays for measuring 
neutralizing antibodies
Considerable research focus has been invested in 
the development of novel serological assays that 
permit efficient and sensitive quantification of 
neutralizing antibodies while addressing persis-
tent problems of containment and expense asso-
ciated with traditional methods. Viruses used in 
‘next-generation’ assays are primarily based on 
the process of manipulating genes that encode 
for structural viral proteins in order to attenu-
ate pathogenicity but maintain a serologically 
equivalent virus. 
Genetically modified & recombinant 
viruses
The genetic recombination of viral genomes 
has been explored in the antigen detection and 
serosurveillance of emerging viruses. 
An attenuated chimeric virus, comprising the 
premembrane and envelope proteins of WNV 
inserted into the yellow fever virus 17D strain 
genome, was produced as a vaccine candidate 
for WNV [35], but was also subsequently used 
as a biosafety level 2 reagent in PRNT studies 
to assess WNV infection histories following the 
1999 outbreak in northeastern USA. As muta-
tions introduced may potentially result in changes 
in immunodominant epitopes, it is important to 
compare the performance of attenuated viruses 
with the wild-type parent virus in serological 
assays. Compared with wild-type WNV, 96% 
of results were concordant when evaluating 
panels of avian and equine sera sampled from 
the outbreak, with high levels of sensitivity and 
specificity and comparable neutralizing antibody 
titers [36]. 
Large-scale codon re-encoding, or codon 
optimization, has also recently been employed 
to attenuate Chikungunya virus as a candidate 
live-attenuated vaccine [37]. The replicative fit-
ness of this alphavirus has been dramatically 
reduced through serial passaging in both pri-
mate and arthropod cells after reassigning an 
infectious Chikungunya virus strain with syn-
onymous codon alterations that, importantly, 
do not confer any coding mutations in the viral 
proteins. 
Such genetic manipulations of emerging 
viruses could have important implications not 
only for vaccine creation, but also for use as 
serological tools for functional antibody detec-
tion without the requirement for high levels of 
containment. 
Reporter virus particles
Reporter virus particles (RVPs) are pseudo-
infectious virions that encapsidate a sub-
genomic RNA replicon (SGR) possessing all of 
the necessary viral nonstructural genes, as well 
as a reporter gene. Although it can be cloned 
into the 3 -´untranslated region of the replicon, 
the reporter gene is usually inserted in place of 
the genomic segments encoding the structural 
envelope and capsid proteins, which are usually 
removed from the replicon system. The SGR is 
then introduced into producer cells along with 
plasmid DNA expression vectors bearing the rel-
evant structural envelope genes, leading to the 
production of RVPs in which only one replicon 
RNA is packaged. These RVPs can be readily 
used to study the antibody-mediated neutral-
ization of specific viruses in serological assays. 
Pierson et al. constructed WNV RVPs by trans-
complementation of the luciferase- or GFP-based 
SGR with plasmids encoding the capsid and pre-
membrane and envelope proteins of the virus [38]. 
The WNV RVPs were used to study the neutral-
izing efficiency of the monoclonal antibody 7H2. 
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RVPs can also be used in serological assays to 
ascertain neutralizing antibody responses against 
a particular viral antigenic epitope, following 
either vaccination or natural infection. One such 
example is the application of GFP-expressing 
RVPs of the four DENV serotypes in a novel 
diagnostic neutralization assay [39]. Results from 
this correlated strongly with those obtained by 
PRNT and were serotype specific, overcoming a 
persistent problem with DENV serology. Using 
RVPs, assays are robust and reproducible, and 
issues of being low throughput that are inherent 
with PRNT-based studies are resolved. 
Pseudotype viruses
Pseudotype viruses (PVs) are increasingly being 
used in serological assays for the diagnosis of viral 
infection or vaccine seroconversion (Table 1). A 
pseudotype is a chimeric virion that comprises 
the structural and enzymatic core of one virus 
and at least one protein or glycoprotein of 
another. Retroviruses can be employed as the 
core for this technology, with lentiviruses and 
gammaretroviruses such as HIV and murine 
leukemia virus also providing an ideal pseudo-
type platform. Rhabdoviruses, such as vesicular 
stomatitis virus (VSV), and other retroviruses, 
such as equine infectious anemia virus, are also 
increasingly used as pseudotype cores. Their 
RNA genomes are manipulated to encode a 
quantifiable marker gene, which is packaged by 
retroviral core proteins. Transduction of the tar-
get cells by the pseudotype is dependent on the 
ability of the envelope protein to engage recep-
tors on the cell surface. If entry is successful, the 
genome is transferred from virus to cell, resulting 
in reporter gene integration and expression. Lev-
els of marker protein expressed in infected cells 
can subsequently be measured, which produces 
a quantitative readout synonymous with the 
function of the foreign envelope glycoprotein [40]. 
PVs are created by simultaneous introduction 
of the envelope gene, retroviral gag–pol genes 
(responsible for the manufacture and enzy-
matic processing of the core structural proteins 
and insertion of the reporter gene into the host 
chromosome) and the chosen reporter gene into 
producer cells such as HEK293 T cells, using a 
three-plasmid cotransfection system, as shown 
in Figure 1. After transcription and translation 
of the imported genes by the relevant cellular 
machinery, an RNA dimer of the reporter gene is 
packaged into the core; these processes are driven 
by an upstream promoter and a packaging sig-
nal, y, respectively. The same packaging signal 
is omitted from the gag–pol construct to prevent 
replication competence and nullify the potential 
risk of pathogenic virus proliferation. PV capsids 
Table 1. Establishment of the pseudotype platform across several families of 
emergent RNA viruses.
Virus family Virus genus and members Core 
vector 
system
Reporter protein Ref.
Orthomyxoviridae Influenza A viruses – various 
subtypes
HIV, MLV Firefly luciferase, GFP [42,65–67]
Rhabdoviridae Lyssavirus – rabies, Lagos bat virus, 
Mokola virus, Duvenhage virus, 
EBLV-1/-2
HIV, MLV, 
EIAV
Firefly luciferase, 
GFP, b-galactosidase
[41,46,47,68]
Coronaviridae Coronavirus – SARS HIV, VSV GFP, b-galactosidase [50,51,69]
Flaviviridae Flavivirus – JEV
Hepacivirus – HCV 
HIV, MLV GFP, b-galactosidase [70,71]
Filoviridae Filovirus – Ebola, Marburg HIV Luciferase [52]
Bunyaviridae Hantavirus – Hantaan, Seoul 
Orthobunyavirus – La Crosse
MLV, VSV GFP, b-galactosidase [54,72]
Paramyxoviridae Henipavirus – Nipah VSV Renilla/firefly 
luciferase, GFP, SEAP
[48,49]
Togaviridae Alphavirus – Ross River virus, 
Chikungunya virus
MLV Luciferase [73,74]
Along with the conventional retroviral vector system, VSV core pseudotyping is also commonly used. Reporter gene 
flexibility within the plasmid cotransfection method for pseudotype production enables cost customization of the 
pseudoparticles, maximizing the scope for laboratories with varying budgets to use the pseudotype system. 
EBLV: European bat lyssavirus; EIAV: Equine infectious anemia virus; JEV: Japanese encephalitis virus; MLV: Murine 
leukemia virus; SARS: Severe acute respiratory syndrome; SEAP: Secreted alkaline phosphatase; VSV: Vesicular 
stomatitis virus.
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are subsequently induced by further signals in 
order to transit to the plasma membrane of the 
producer cell before they bud extracellularly. The 
virus envelope bearing the heterologous glyco-
protein is formed from the plasma membrane 
[40]. This process results in a virus-rich superna-
tant of culture medium, which can be harvested 
and titrated on the target cell. The reporter 
gene is flanked by long tandem repeats; these 
facilitate integration into the target cell genome. 
Integration is catalyzed by the lentiviral poly-
merase/integrase, which is packaged as part of 
the pseudotype virion. The titer of the PV is cal-
culated as a function of reporter gene expression.
Functional PV particles can be used as ‘surro-
gate viruses’ in neutralization assays to ascertain 
the immune response of neutralizing antibodies 
raised against the envelope glycoprotein coating 
the pseudotype. Neutralization is quantified as 
a decrease in reporter gene expression compared 
with the original pseudotype transduction titer. 
This avoids the use of native, pathogenic virus in 
current serological assays, dramatically widening 
the scope of laboratories able to effectively diagnose 
suspected cases of viral infection. Another advan-
tage of the pseudotype neutralization assay (PNA) 
is the small sample volume required (≤10 µl), as 
evidenced by a recent study employing PNA 
iv
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Figure 1. Three-plasmid cotransfection method for pseudotype virus production. (A) Conventional plasmid DNA expression 
vectors bearing (i) the HIV gag–pol gene, (ii) the envelope glycoprotein from the virus of interest or (iii) a reporter gene (e.g., luciferase) 
are generated. (B) All three plasmids are transfected into ‘producer’ cells (e.g., HEK293 T cells). (C) Supernatants are harvested at 48 h 
post-transfection and produced pseudotype viruses (PVs) are titrated onto target cells expressing receptors recognized by the envelope 
protein in order to ascertain a relative transduction titer. (D) PVs can be subsequently employed as surrogate viruses in pseudotype 
neutralization assays to quantify VNAb responses. Titrated patient samples are preincubated with a fixed titer of PV before addition to 
target cells. (iv) In the absence of VNAbs, the envelope protein of the virus of interest enables entry of the PV into the target cell and the 
reporter gene is integrated and expressed. (v) Binding of the envelope protein by specific antibodies in the sample blocks entry of the PV 
into the target cell, thus preventing expression of the reporter gene. As for traditional plaque reduction neutralization tests, the titer of 
antibody can be expressed as the highest dilution of sample that inhibits expression by 50 or 90%. 
LTR: Long tandem repeat; VNAb: Virus-neutralizing antibody.
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methodology to quantify Lagos bat virus (LBV), 
Mokola virus (MOKV) and West Caucasian bat 
virus VNAbs in African fruit bat populations [41]. 
Pseudotype technology for diagnostic serol-
ogy has now been explored for many groups 
of viruses, and several robust and reproducible 
neutralization assays have been developed. The 
influenza pseudotype platform is among the best 
established, with the majority of initial emphasis 
being placed on subtypes responsible for notori-
ous zoonotic outbreaks in the human population, 
such as H5N1 highly pathogenic avian influenza 
[42]. Recent elaborations include the production 
of lentiviral pseudotypes bearing the heterolo-
gous hemagglutinin of highly pathogenic avian 
H7 strains and representatives of each of the 
group 2 influenza A virus subtypes, including 
equine H3 [43–45]. This will facilitate heterosub-
typic serosurveillance in regions where resources 
are limited, which will be highly beneficial for 
the early anticipation of zoonotic transmission 
of influenza subtypes with pandemic potential. 
Large-scale, in-field serodiagnostic studies have 
also been performed using pseudotypes of rabies 
and other lyssaviruses [46,47]. Pseudotype neu-
tralization tests provided a specific diagnosis, 
distinguishing between different lyssavirus infec-
tions, and their results correlated strongly with 
validated serological assays. Indeed in some cases, 
the PNAs were more sensitive. Other emerging 
viruses to which pseudoparticle technology has 
been applied are Nipah, using a VSV vector [48,49], 
as well as SARS coronavirus [50,51], Marburg and 
Ebola filoviruses [52,53] and Hantaan and Seoul 
hantaviruses [54]. 
The generation of PVs can pose some chal-
lenges. Although most of the PVs generated so far 
express a single viral envelope protein, expression 
of two envelope proteins may be a prerequisite 
for successful generation of a PV, as is the case 
for HCV [55]. Furthermore, critical processes in 
the maturation and assembly of the envelope pro-
teins in the wild-type virus may be lost in the 
generation of a PV. For example, particle forma-
tion of lentiviruses occurs at the plasma mem-
brane, whereas for flaviviruses, it occurs at the 
endoplasmic reticulum. Hsu et al. overcame this 
obstacle by replacing the transmembrane domain 
of the DENV envelope protein with the trans-
membrane and cytoplasmic domains of the VSV 
glycoprotein [55]. Kolokoltsov et al. observed that 
the density of Venezuelan equine encephalitis 
envelope proteins was reduced in PVs [56]. This 
may result in the loss of quaternary epitopes cre-
ated by tightly packed envelope proteins, which 
may be important VNAb targets [57]. Similarly 
to genetically modified virus assays, it is therefore 
important to carefully compare results obtained 
with assays using PVs with those from traditional 
assays using wild-type virus. On the other hand, 
greater maturation of WNV envelope protein 
has been shown to reduce the sensitivity of RVPs 
to neutralization due to masking of epitopes 
that are accessible and recognized by the host 
immune system during infection [58].
Further advances
Wright et al. have explored the potential of multi-
plexing the PV system as a means for simultane-
ous screening of VNAb responses to more than 
one virus in diagnostic and sero surveillance 
studies [41]. Renilla or firefly luciferase reporter 
genes were incorporated into pseudotyped par-
ticles bearing the envelope proteins for LBV 
and MOKV, respectively. LBV and MOKV 
are phylogroup 2 lyssaviruses that are clinically 
indistinguishable. A dual PNA was performed 
in which renilla and firefly luciferase expression 
were quantified. Results from the duplex assay 
correlated well with those from PNAs using the 
individual pseudotypes, and overall seropreva-
lence of the two lyssaviruses within an Eidolon 
helvum bat reservoir was in accordance with 
previous studies [59,60]. The ability to multiplex 
the pseudotype platform enables resource-poor 
laboratories to detect VNAbs for several viruses 
at once, reducing the necessary reagent and 
sample volumes. The system could be further 
multiplexed by use of fluorescent markers such 
as GFP and RFP for additional PVs. Ultimately, 
serological assays could be carried out for whole 
families of emerging viruses, such as henipa-
viruses, corona viruses and hantaviruses, which 
have already been adapted to the pseudotype 
system. 
The flexibility of reporter genes that can be 
incorporated into the cotransfection stage of 
pseudoparticle production is a major advantage 
of the viral pseudotyping approach. The most 
frequently used reporter genes are GFP, firefly 
luciferase and renilla luciferase. Switching of 
these genes has been facilitated by the develop-
ment of a common HIV plasmid construct, into 
which each reporter has been subcloned: pCSGW, 
pCSFLW and pCSRLW, respectively [47,51,61]. 
Luciferase can be regarded as the ‘gold standard’ 
reporter gene for the pseudotype platform, with 
respect to the assay’s readout preparation time 
and quantitative data analysis, although the cost 
of luciferase reagent kits and the necessity for 
specialist detection equipment may restrict its 
widespread application. Use of a GFP reporter 
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does not necessitate additional reagents for read-
ing neutralization titers, but nevertheless requires 
relatively expensive readout equipment, such as a 
fluorescent microscope. Therefore, the production 
and expression of cheaper, alternative reporters is 
of vital importance. b-galactosidase substrates can 
be used to quantify pseudotype and VNAb titers 
by the introduction of the lacZ gene as a reporter 
(pCSLZW). The readout can be obtained in a 
cost-effective fashion, either by counting cells 
under a light microscope after incubation with 
5-bromo-4-chloro-3-indolyl-b-d-galactopyrano-
side (X-gal) or by the evaluation of a colorimetric 
substrate – either O-nitrophenyl-b-d-lactopyran-
oside (ONPG) or chlorophenol red-b-d-galacto-
pyranoside (CPRG) – using an ELISA plate reader 
or by eye [46]. A further development in the choice 
of reporter system is the use of secreted alkaline 
phosphatase, which was recently incorporated 
and expressed in Nipah virus pseudotypes [62]. 
In serological assays, secreted alkaline phospha-
tase is independently secreted into the cell culture 
supernatant with no need for an additional read-
out substrate or lysing agent. A colorimetric reac-
tion develops and results are obtained within 24 h 
of the initial infection, which is more rapid than 
established pseudotype titration or neutralization 
protocols. High-throughput screening of antisera 
could be undertaken and measured in an inexpen-
sive ELISA plate reader, similar to b-galactosidase 
expression systems. 
A rapid-entry assay first described by Kolo-
koltsov and Davey provides a potential solution 
to the lengthy incubation required for a read-out 
to be determined, which can be in the region of 
48–72 h [56], for laboratories with sufficient fund-
ing to regularly carry out luciferase- and GFP-
based pseudotype assays. Virus-encapsulated 
luciferase bound to a Nef accessory protein is 
incorporated into PV particles. Upon transduc-
tion of the virus into the target cell, the Nef–lucif-
erase complex is released into the cytosol. Lucif-
erin introduction creates a rapid light- emitting 
reaction that can be quantified using a lumino-
meter. This technique circumvents the incubation 
period required for assays that are reliant on the 
integration and expression of a plasmid- derived 
reporter gene. Using this assay, viral entry signals 
were detected in as short a period as 15 min with 
high specificity and low background readings that 
are comparable with similar serological tests. 
Conclusion
The promise of genetic modification of viruses 
and the production of ‘next-generation’ serologi-
cal assays is undeniable. However, they cannot 
yet compete with the more traditional assays in 
terms of speed of development. Further advances 
must now be made with regard to cost, dissemi-
nation and speed of acquiring results to maximize 
the utility of these assay platforms. 
Future perspective
Before any serological assays are adopted for 
high-throughput diagnostic applications, they 
must undergo rigorous, extensive validation in 
order to achieve necessary certification and rec-
ognition by international public health boards, 
such as the WHO or the World Organization 
for Animal Health (OIE). Some measures have 
been taken to clinically ratify the sensitivity of 
novel serological tests in comparison to their 
more established counterparts. For instance, a 
large panel of avian sera sampled from a par-
tially vaccinated population of Vietnamese ducks 
and chickens was recently screened for H5N1 
influenza using a PNA, as well as an HI test and 
an H5-specific ELISA, before comparisons were 
made between the three tests. In this study, the 
PNA was considered a ‘gold standard’ reference 
assay, and the results revealed a comparably low 
specificity when values close to the positive cutoff 
value were obtained in the H5-specific ELISA, 
as well as reinforcing the accurate, sensitive 
performances of the PNA and HI tests, which 
correlated very strongly [63]. 
Optimization of the relevant protocols and 
reagents to ensure accuracy and reproducibility, 
as well as the establishment of reference sera of 
known VNAb titers that can be made available 
through national and international bodies, such 
as the European Pharmacopoeia [64], are other 
factors that are integral to increasing the prob-
ability of novel serological assays transcending 
the divide from proof of concept to significantly 
influencing public health and reducing the inci-
dence of emerging infectious viruses. These 
processes are also vital in minimizing interlabo-
ratory variation of ‘next-generation’ serologi-
cal assays, enabling their effective use for the 
purposes of diagnosis and serosurveillance. 
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Traditional serological assays
	n The plaque reduction neutralization test is considered the ‘gold standard’ serological assay for viral infection due to its high sensitivity 
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	n Hemagglutination inhibition is a widespread, high-throughput serological approach in comparison with the plaque reduction 
neutralization test, but it also detects non-neutralizing antibodies and can be subject to interlaboratory variations due to difficulties 
concerning reagent standardization.
	n ELISA is another high-throughput assay with the ability to utilize the differentiation of infected from vaccinated animals (DIVA) 
approach in vaccine evaluation schemes, but this serological assay can be prone to low sensitivity and high levels of cross-reactivity in 
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‘Next-generation’ assays for detecting neutralizing antibodies
	n Novel serological techniques often revolve around the ability to attenuate or genetically alter a virus, decreasing its pathogenicity and 
thus enabling its use as a surrogate reagent in either traditional or ‘next-generation’ assays.
	n Recombinant viruses are usually exploited as attenuated vaccine candidates, but they can also be valuable in serology, being utilized 
in place of wild-type virus subsequent to genetic augmentations, such as codon deoptimization or envelope glycoprotein gene 
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	n Reporter virus particles encapsidate a subgenomic RNA replicon capable of expressing a reporter gene upon target cell infection, with 
reporter virus particle production being accomplished by trans-complementation of replicon RNA with virus structural genes cloned into 
plasmid DNA expression vectors.
	n Pseudotype viruses are produced via multiplasmid cotransfection systems – they comprise a retroviral core vector displaying foreign 
envelope glycoproteins and harboring a reporter gene, and are ideal surrogates for pathogenic virus in neutralization assays.
Further advances
	n The ability to multiplex the pseudotype system has considerable beneficial implications for increasing assay throughput, reducing 
volumes of valuable reagents and thus saving on the cost-per-assay burden of this platform.
	n Flexibility to choose which pseudotype virus reporter gene is integrated into target cell chromosomes enables the cost customization of 
the platform – luciferase and GFP reporters have more expensive associated costs, whereas b-galactosidase expression can be 
quantified very affordably.
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providing an ideal solution to throughput dilemmas, as results can be measured within 15 min of assay preparation.
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